GLP-1 medicines are prescription medicines that help some people manage weight and/or type 2 diabetes by reducing appetite, changing how quickly food leaves the stomach, and improving blood sugar control. In everyday UK chat they're often called "weight loss jabs", but the proper term is usually GLP-1 receptor agonists (and closely related medicines, like tirzepatide, that act on more than one hormone pathway).
People often use “GLP-1” as a catch-all for newer weight management injections, but there are two useful distinctions:
If you're writing or talking about these medicines in a way that's accurate and easy to understand, “GLP-1 medicines” is fine — just note that some newer injections are dual-acting. For a full list of terms, see the GLP-1 glossary.
GLP-1 medicines mimic (or amplify) signals your body already uses after eating. In practice, that tends to show up in a few ways:
Below is a practical “name mapping” table because most confusion online is just brand names versus ingredients.
| Ingredient | Brand name (UK) | Typical use | How it's taken |
|---|---|---|---|
| Semaglutide | Wegovy | Weight management | Injection (weekly) |
| Semaglutide | Ozempic | Type 2 diabetes | Injection (weekly) |
| Tirzepatide (dual GIP/GLP-1) | Mounjaro | Type 2 diabetes and weight management (NICE-approved for eligible adults) | Injection (weekly) |
| Liraglutide | Saxenda | Weight management | Injection (daily) |
This is not an exhaustive list. There are other GLP-1 medicines used for diabetes, and what's appropriate depends on your clinical context. See the GLP-1 glossary for more terms.
Trials give a useful “order of magnitude”, but they're averages under specific conditions (and you're a person, not a mean).
That doesn't mean you “should” lose those percentages (or that it will feel easy). It does mean: these medicines can be powerful tools, but outcomes vary, and the long-term question becomes, “How do you maintain what you've built?” Read more about GLP-1 weight loss in the UK.
If you have symptoms that could indicate something serious (particularly severe, persistent abdominal pain), treat that as an “ask for urgent clinical advice” situation rather than trying to self-interpret. Learn more about what Healthcount does and does not do.
Early weight loss can feel like momentum; maintenance is the part where small drifts compound.
One reason maintenance deserves its own plan is that stopping treatment is often followed by weight regain. In the STEP 1 trial extension, participants regained about two-thirds of prior weight loss one year after stopping semaglutide (with cardiometabolic markers trending back too). Read the full evidence on weight regain after stopping GLP-1.
So, when people talk about “willpower”, it's often missing the point — obesity is chronic, and the body pushes back. The useful question becomes: what low-burden system helps you spot drift early, before it becomes a full reset?
Learn more about GLP-1 maintenance and why people stop GLP-1.
Healthcount treats maintenance as a measurement problem. Think of it like a sat-nav for GLP-1 maintenance: it watches your trend line rather than every daily wobble, and it nudges you when the signals suggest drift (so you can act early, rather than after weeks of slippage).
See how Healthcount works and our clinical boundaries.
If you're considering or already using a GLP-1 medicine, these questions may be useful at your next appointment:
Last updated: March 2026. For our editorial approach, see our clinical boundaries and Privacy & UK GDPR.
Understand what drift looks like and how to respond — or request a pilot if you're an insurer or employer.